Datopotamab deruxtecan by Daiichi Sankyo for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
What's Your Reaction?
